TN2014000454A1 - Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy - Google Patents
Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapyInfo
- Publication number
- TN2014000454A1 TN2014000454A1 TN2014000454A TN2014000454A TN2014000454A1 TN 2014000454 A1 TN2014000454 A1 TN 2014000454A1 TN 2014000454 A TN2014000454 A TN 2014000454A TN 2014000454 A TN2014000454 A TN 2014000454A TN 2014000454 A1 TN2014000454 A1 TN 2014000454A1
- Authority
- TN
- Tunisia
- Prior art keywords
- gcc
- antibody molecules
- targeted therapy
- methods
- antibodies
- Prior art date
Links
- 238000002626 targeted therapy Methods 0.000 title abstract 3
- 229940127121 immunoconjugate Drugs 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 238000009175 antibody therapy Methods 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639376P | 2012-04-27 | 2012-04-27 | |
| PCT/US2013/038542 WO2013163633A1 (en) | 2012-04-27 | 2013-04-27 | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2014000454A1 true TN2014000454A1 (en) | 2016-03-30 |
Family
ID=49477498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TN2014000454A TN2014000454A1 (en) | 2012-04-27 | 2014-10-24 | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy |
Country Status (41)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3031851C (en) | 2009-10-23 | 2020-07-07 | Amgen British Columbia | Anti-gcc antibody molecules and related compositions and methods |
| WO2015058301A1 (en) * | 2013-10-21 | 2015-04-30 | The Centre For Drug Research And Development | Anti-podocalyxin antibodies and methods of using the same |
| CA2936907C (en) | 2014-02-14 | 2022-06-07 | Arkansas Children's Hospital Research Institute, Inc. | Acetaminophen protein adducts and methods of use thereof |
| AU2015358373B2 (en) * | 2014-12-03 | 2021-05-27 | Arkansas Children's Research Institute | Anti-acetaminophen antibodies and acetaminophen protein adducts |
| CN109311994B (zh) | 2015-10-01 | 2022-06-07 | 药物研究及发展中心 | 抗足糖萼蛋白抗体及其使用方法 |
| JP7356351B2 (ja) * | 2016-12-12 | 2023-10-04 | エクセラ・バイオサイエンシーズ・インコーポレイテッド | マイクロキャピラリーアレイを使用したスクリーニングのための方法およびシステム |
| KR102080887B1 (ko) * | 2017-11-07 | 2020-02-24 | 고려대학교 산학협력단 | Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물 |
| US11568657B2 (en) | 2017-12-06 | 2023-01-31 | Ventana Medical Systems, Inc. | Method of storing and retrieving digital pathology analysis results |
| WO2019110561A1 (en) * | 2017-12-06 | 2019-06-13 | Ventana Medical Systems, Inc. | Method of storing and retrieving digital pathology analysis results |
| FI3846788T3 (fi) * | 2018-09-05 | 2025-12-17 | Univ Amsterdam | Pde11-estäjiä parkinsonin taudin hoitoon |
| WO2021205325A1 (en) * | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
| IL296519A (en) * | 2020-06-02 | 2022-11-01 | Teijin Pharma Ltd | Anti-igf-1 receptor humanized antibody |
| CN118146381A (zh) * | 2020-12-17 | 2024-06-07 | 合肥梧桐生物科技有限公司 | Gucy2c结合分子及其用途 |
| WO2022216079A1 (ko) * | 2021-04-07 | 2022-10-13 | 주식회사 엘지화학 | Gucy2c 결합 폴리펩타이드 및 그의 용도 |
| EP4594364A1 (en) * | 2022-09-28 | 2025-08-06 | Legend Biotech Ireland Limited | Antibody and chimeric antigen receptors targeting gcc and methods of use thereof |
| AR130916A1 (es) | 2022-11-01 | 2025-01-29 | Heidelberg Pharma Res Gmbh | Anticuerpo anti-gucy2c y usos del mismo |
| CN116535514B (zh) * | 2023-06-15 | 2024-02-02 | 上海斯丹赛生物技术有限公司 | 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用 |
| CN117069848B (zh) * | 2023-08-02 | 2025-02-28 | 武汉爱博泰克生物科技有限公司 | 抗人cd146兔单克隆抗体及其应用 |
| WO2025061149A1 (zh) * | 2023-09-21 | 2025-03-27 | 南京传奇生物科技有限公司 | 抗gcc抗体、嵌合抗原受体及其用途 |
| EP4566631A1 (en) | 2023-12-06 | 2025-06-11 | Heidelberg Pharma Research GmbH | New antibody drug conjugate as well as methods of production and uses thereof |
| CN120965861A (zh) * | 2025-10-22 | 2025-11-18 | 杭州博茵生物技术有限公司 | 一种Fc效应消除的新型骨架流式抗体及其制备方法与应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5237051A (en) | 1990-12-06 | 1993-08-17 | Vanderbilt University | Purified enterotoxin receptor protein |
| US5601990A (en) | 1994-09-13 | 1997-02-11 | Thomas Jefferson University | Methods of diagnosing colorectal tumors and metastasis thereof |
| US5879656A (en) | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
| US5518888A (en) | 1993-10-26 | 1996-05-21 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
| US7097839B1 (en) | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
| US6060037A (en) | 1993-10-26 | 2000-05-09 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| US6455251B1 (en) | 1994-09-13 | 2002-09-24 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
| CA2254082C (en) | 1996-05-03 | 2012-09-11 | Thomas Jefferson University | Metastatic colorectal cancer vaccine |
| US6602659B1 (en) | 1996-05-03 | 2003-08-05 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
| US6120995A (en) | 1997-08-07 | 2000-09-19 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
| US8092514B1 (en) | 1998-11-16 | 2012-01-10 | Boston Scientific Scimed, Inc. | Stretchable anti-buckling coiled-sheet stent |
| US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
| WO2001073133A1 (en) | 2000-03-27 | 2001-10-04 | Thomas Jefferson University | Compositions and methods for identifying and targeting cancer cells |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| ES2372686T3 (es) | 2001-01-26 | 2012-01-25 | Inhibitex, Inc. | Anitcuerpos monoclonales dirigidos contra la proteína clfa y modo de empleo en el tratamiento y prevención de infecciones. |
| JP4206272B2 (ja) | 2001-03-29 | 2009-01-07 | サイナージィ ファーマスーティカルズ、インコーポレイテッド | 組織炎症及び発癌を治療するためのグアニル酸シクラーゼ受容体アゴニスト |
| NZ529494A (en) | 2001-04-13 | 2005-08-26 | Biogen Idec Inc | Antibodies to VLA-1 |
| WO2003057838A2 (en) | 2001-12-28 | 2003-07-17 | Abgenix, Inc. | Antibodies against the muc18 antigen |
| US20040110933A1 (en) | 2002-09-13 | 2004-06-10 | Dyax Corporation | CD44-binding ligands |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US8206704B2 (en) | 2003-02-10 | 2012-06-26 | Thomas Jefferson University | Use of GCC ligands |
| CA2525120C (en) | 2003-05-14 | 2013-04-30 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
| US7871610B2 (en) | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
| EP2722060A3 (en) | 2004-06-25 | 2015-01-07 | Thomas Jefferson University | Guanylyl cyclase C ligands |
| US20080267971A1 (en) | 2004-12-21 | 2008-10-30 | Green Larry L | Antibodies Directed to Angiopoietin-2 and Uses Thereof |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| CN103601792B (zh) | 2007-06-04 | 2016-06-29 | 协同医药品公司 | 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂 |
| PL2188306T3 (pl) * | 2007-08-10 | 2017-01-31 | Janssen Biotech, Inc. | Fragmenty powstałe po cięciu immunoglobuliny jako wskaźniki choroby oraz kompozycje do ich wykrywania i wiązania |
| MY161564A (en) | 2007-08-10 | 2017-04-28 | Regeneron Pharma | High affinity human antibodies to human nerve growth factor |
| RS51987B (sr) * | 2007-11-30 | 2012-02-29 | Genentech Inc. | Vegf polimorphizmi i anti-angiogenezna terapija |
| CA2760050A1 (en) | 2008-05-13 | 2009-11-19 | Thomas Jefferson University | Guanylyl cyclase c qrt-pcr |
| JP2011523662A (ja) | 2008-06-04 | 2011-08-18 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| WO2010065293A1 (en) * | 2008-12-03 | 2010-06-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Antibodies for guanylyl cyclase receptors |
| PL2881402T3 (pl) * | 2009-02-12 | 2017-10-31 | Cell Signaling Technology Inc | Ekspresja zmutowanej ROS w ludzkim raku wątroby |
| AU2010217160C1 (en) | 2009-02-25 | 2015-07-02 | Diagnocure Inc. | Method for detecting metastasis of GI cancer |
| WO2010104035A1 (ja) * | 2009-03-12 | 2010-09-16 | 学校法人近畿大学 | 非小細胞肺癌に対する化学療法の治療効果予測方法 |
| CA2801729A1 (en) | 2009-06-15 | 2010-12-23 | Thomas Jefferson University | Compositions for and methods of activating guanylyl cyclase c |
| US20120251509A1 (en) | 2009-10-22 | 2012-10-04 | Waldman Scott A | Cell-based anti-cancer compositions and methods of making and using the same |
| CA3031851C (en) * | 2009-10-23 | 2020-07-07 | Amgen British Columbia | Anti-gcc antibody molecules and related compositions and methods |
| US9169329B2 (en) * | 2010-06-01 | 2015-10-27 | Ludwig Institute For Cancer Research | Antibodies directed to the receptor tyrosine kinase c-Met |
| KR20140003393A (ko) * | 2010-08-13 | 2014-01-09 | 에프. 호프만-라 로슈 아게 | 베바시주맙 병용 치료법을 위한 바이오마커인 뉴로필린 |
| US20150086481A1 (en) | 2011-07-28 | 2015-03-26 | Memorial Sloan-Kettering Cancer Center | Diagnosis and treatment of parkinson's disease |
| US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
| KR20150122730A (ko) * | 2013-02-28 | 2015-11-02 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 암의 치료에서 항-gcc 항체-약물 콘주게이트 및 dna 손상 제제의 투여 |
-
2013
- 2013-04-27 KR KR1020147032890A patent/KR102046435B1/ko not_active Expired - Fee Related
- 2013-04-27 ME MEP-2019-257A patent/ME03560B/me unknown
- 2013-04-27 US US13/872,080 patent/US9000129B2/en active Active
- 2013-04-27 PL PL13782061T patent/PL2841575T3/pl unknown
- 2013-04-27 LT LTEP13782061.9T patent/LT2841575T/lt unknown
- 2013-04-27 JP JP2015509208A patent/JP6472746B2/ja active Active
- 2013-04-27 SM SM20190536T patent/SMT201900536T1/it unknown
- 2013-04-27 ES ES13782061T patent/ES2749181T3/es active Active
- 2013-04-27 SI SI201331582T patent/SI2841575T1/sl unknown
- 2013-04-27 RS RSP20191239 patent/RS59370B1/sr unknown
- 2013-04-27 PE PE2014001908A patent/PE20142322A1/es active IP Right Grant
- 2013-04-27 HR HRP20191690TT patent/HRP20191690T1/hr unknown
- 2013-04-27 EP EP13782061.9A patent/EP2841575B1/en active Active
- 2013-04-27 PT PT137820619T patent/PT2841575T/pt unknown
- 2013-04-27 SG SG11201406855TA patent/SG11201406855TA/en unknown
- 2013-04-27 SA SA113340502A patent/SA113340502B1/ar unknown
- 2013-04-27 CN CN201380033309.4A patent/CN104395470B/zh active Active
- 2013-04-27 UA UAA201412715A patent/UA117910C2/uk unknown
- 2013-04-27 HU HUE13782061A patent/HUE046404T2/hu unknown
- 2013-04-27 WO PCT/US2013/038542 patent/WO2013163633A1/en not_active Ceased
- 2013-04-27 MA MA37569A patent/MA37569B1/fr unknown
- 2013-04-27 CA CA2871614A patent/CA2871614C/en active Active
- 2013-04-27 GE GEAP201313644A patent/GEP201706737B/en unknown
- 2013-04-27 MY MYPI2014703176A patent/MY188442A/en unknown
- 2013-04-27 NZ NZ701601A patent/NZ701601A/en not_active IP Right Cessation
- 2013-04-27 EA EA201491977A patent/EA034689B1/ru unknown
- 2013-04-27 DK DK13782061.9T patent/DK2841575T3/da active
- 2013-04-27 AU AU2013251312A patent/AU2013251312B2/en not_active Ceased
- 2013-04-27 MX MX2014013081A patent/MX362020B/es active IP Right Grant
- 2013-04-29 TW TW102115363A patent/TWI631137B/zh active
- 2013-04-29 AR ARP130101458A patent/AR090884A1/es active IP Right Grant
-
2014
- 2014-10-23 IL IL235307A patent/IL235307B/en active IP Right Grant
- 2014-10-23 ZA ZA2014/07723A patent/ZA201407723B/en unknown
- 2014-10-24 DO DO2014000242A patent/DOP2014000242A/es unknown
- 2014-10-24 PH PH12014502399A patent/PH12014502399B1/en unknown
- 2014-10-24 TN TN2014000454A patent/TN2014000454A1/fr unknown
- 2014-10-27 CL CL2014002911A patent/CL2014002911A1/es unknown
- 2014-10-27 CR CR20140497A patent/CR20140497A/es unknown
- 2014-11-25 EC ECIEPI201428523A patent/ECSP14028523A/es unknown
- 2014-11-26 CO CO14260074A patent/CO7280144A2/es unknown
-
2015
- 2015-02-27 US US14/634,438 patent/US9273146B1/en active Active
-
2016
- 2016-01-19 US US15/000,950 patent/US20160130344A1/en not_active Abandoned
-
2017
- 2017-04-26 JP JP2017087084A patent/JP6517267B2/ja active Active
-
2019
- 2019-09-24 CY CY20191101005T patent/CY1122557T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2014000454A1 (en) | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy | |
| Poole | Measures of hand function: arthritis hand function test (AHFT), Australian Canadian osteoarthritis hand index (AUSCAN), Cochin hand function scale, functional index for hand osteoarthritis (FIHOA), grip ability test (GAT), Jebsen hand function test (JHFT), and Michigan hand outcomes questionnaire (MHQ) | |
| BR112018005322A2 (pt) | anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos | |
| CY1121392T1 (el) | Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης | |
| MX383886B (es) | Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo. | |
| WO2009085216A3 (en) | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease | |
| WO2010059969A3 (en) | Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer | |
| EA201791876A1 (ru) | Моноклональные антитела к прогастрину и их применение | |
| EA201291260A1 (ru) | Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo | |
| MX2013002084A (es) | Biomarcadores y metodos de tratamiento. | |
| BR112012012610A2 (pt) | terapia de combinação para o tratamento de câncer e ensaios diagnósticos para o uso na mesma | |
| WO2014036495A3 (en) | Diagnostic assays and kits for detection of folate receptor 1 | |
| EA201100923A1 (ru) | Антитела человека против тканевого фактора | |
| MX2018011832A (es) | Metodos y composiciones para uso en diagnostico de pacientes con cancer. | |
| BR112014016299A8 (pt) | imunoglobulinas de domínio variável e usos das mesmas | |
| BR112016002000A2 (pt) | Diagnóstico e terapia de câncer envolvendo células-tronco tumorais | |
| WO2011015333A3 (en) | Targeting of bone marrow neovasculature | |
| CY1120063T1 (el) | Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo | |
| MX2010005057A (es) | Metodos y composiciones para uso de diagnostico en pacientes de cancer. | |
| WO2015013508A3 (en) | Methods for diagnosing and treating immune disease | |
| FR2979346B1 (fr) | Nanocorps anti-vcam-1 | |
| BRPI0923652A2 (pt) | diagnóstico e tratamento de câncer usando anticorpo anti-lgr7 | |
| BR112015031950A2 (pt) | métodos para tratamento de câncer de ovário | |
| WO2012119989A3 (en) | Antibodies against cadmi for the diagnosis and treatment of cancer | |
| TH1401006471A (th) | โมเลกุลแอนติบอดีต้าน gcc และการใช้โมเลกุลดังกล่าวเพื่อทดสอบภูมิไวรับต่อการรักษาที่มุ่งเป้าไปที่ gcc |